IMPROVE-IT
- 18,000 participants
- 8 sites in New Zealand
- 1,500 sites globally
IMPROVE IT – IMProved Reduction of Outcomes: Vytorin Efficacy International Trial.
A Multicentre, Double-Blind, Randomised Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome.
The main aim of the trial is to evaluate the benefit of Vytorin (study medication) compared to Simvastatin (control therapy) in participants who have experienced a heart attack or chest pain which required treatment in a hospital. This is a phase IIIb trial meaning that both of the medications that will be used in the trial have been approved by the government for use by doctors in New Zealand.